Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion.
A CRISPR rat with full Ube3a deletion copies Angelman motor and memory deficits, giving behavior analysts a pre-clinical model for quick, low-cost intervention tests.
01Research in Context
What this study did
Andie et al. (2020) used CRISPR to delete the whole Ube3a gene in rats. The goal was to build a new lab animal that shows the same movement and memory problems seen in children with Angelman syndrome.
The team checked that the rats lacked the gene and then looked for hallmark traits like poor balance and slow learning.
What they found
The rats without Ube3a moved clumsily and had trouble remembering maze paths. These deficits mirror the motor and cognitive issues seen in people with Angelman syndrome.
Because the symptoms match, the rats can serve as a stand-in for testing future ABA-based or drug interventions.
How this fits with other research
Strachan et al. (2009) studied real children with Angelman syndrome and found that most aggression happened during rich social play, not when the kids wanted attention. The new rat model gives us a way to study brain circuits behind that social drive without invasive work on humans.
Scior et al. (2023) created a parent-report tool called ORCA to track communication in Angelman syndrome. Once therapies are tested in the Ube3a rats, ORCA could be the human endpoint to see if lab gains turn into real-world communication gains.
Reinders (2008) built a cheap, automated rat station for smell and touch tasks. The same rig can now be dropped into the Ube3a rat colony to measure learning speed after behavioral interventions, saving labs time and money.
Why it matters
You now have a validated rat model that copies the motor and memory issues of Angelman syndrome. Use it to pilot new teaching procedures or reinforcement schedules before trying them with clients. Pair the rat data with ORCA scores to show parents clear, evidence-based progress.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Draft a pilot study using the H (2008) automated station to track how many trials Ube3a rats need to master a tactile discrimination, then mirror that protocol in your next Angelman case to set realistic trial counts.
02At a glance
03Original abstract
Angelman syndrome (AS) is a rare genetic disorder characterized by severe intellectual disability, seizures, lack of speech, and ataxia. The gene responsible for AS was identified as Ube3a and it encodes for E6AP, an E3 ubiquitin ligase. Currently, there is very little known about E6AP's mechanism of action in vivo or how the lack of this protein in neurons may contribute to the AS phenotype. Elucidating the mechanistic action of E6AP would enhance our understanding of AS and drive current research into new avenues that could lead to novel therapeutic approaches that target E6AP's various functions. To facilitate the study of AS, we have generated a novel rat model in which we deleted the rat Ube3a gene using CRISPR. The AS rat phenotypically mirrors human AS with loss of Ube3a expression in the brain and deficits in motor coordination as well as learning and memory. This model offers a new avenue for the study of AS. Autism Res 2020, 13: 397-409. © 2020 International Society for Autism Research,Wiley Periodicals, Inc. LAY SUMMARY: Angelman syndrome (AS) is a rare genetic disorder characterized by severe intellectual disability, seizures, difficulty speaking, and ataxia. The gene responsible for AS was identified as UBE3A, yet very little is known about its function in vivo or how the lack of this protein in neurons may contribute to the AS phenotype. To facilitate the study of AS, we have generated a novel rat model in which we deleted the rat Ube3a gene using CRISPR. The AS rat mirrors human AS with loss of Ube3a expression in the brain and deficits in motor coordination as well as learning and memory. This model offers a new avenue for the study of AS.
Autism research : official journal of the International Society for Autism Research, 2020 · doi:10.1002/aur.2267